FINWIRES · TerminalLIVE
FINWIRES

Orezone Set for a Stronger Second Half, Says Euroz Hartleys

By

-- Orezone (ASX:ORE) is poised for a stronger second half of 2026 after easing emulsion supply issues and the closing of Casa Berardi acquisition in March, which is ramping up production and exploration, Euroz Hartleys said in a note on Monday.

In the first quarter, the company's gold production rose 24% quarter-on-quarter to 38,789 ounces, even as performance was slightly affected by intermittent emulsion deliveries required for planned hard rock blasting, leading to lower grades in contrast to better-than-expected mill performance.

The company kept its Bomboré operations 2026 gold production guidance unchanged at 160,000 ounces to 180,000 ounces, in line with Euroz Hartleys' estimate of 173,000 ounces.

The investment firm reaffirmed its speculative buy rating and raised its price target to AU$4.35 from AU$4.25.

Related Articles

International

Japan's Unemployment Rate Ticks Up to 2.7% in March

Japan's unemployment rate inched up to 2.7% in March compared with the previous month's 2.6%, according to government data released on Tuesday.The data showed that the number of employed decreased slightly to a seasonally adjusted 68.15 million from 68.27 million in February, while the number of jobless people increased to 1.86 million from 1.85 million the prior month.

$^N225
Asia

Market Chatter: Japan Faces Risk of Missing on New Drugs Due to US Pricing Model

Japan may miss out on breakthrough drugs because a U.S. pricing model threatens to link American drug costs to lower Japanese prices under the most favored nation (MFN) plan, Nikkei reported on Tuesday.Under the plan, the U.S. would reference prices from countries, including Japan, for Medicare and Medicaid, though companies could avoid this by not launching products in Japan, the news daily said.This could lead pharmaceutical firms to delay or skip entering the Japanese market, while Japan might face upward pressure on drug prices and higher social insurance costs, the publication said.Industry groups are urging Japan to reassess its pricing rules to align innovative drug prices with international levels and maintain them during patent periods, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^N225
Asia

Echo IQ Deploys AI-Based Decision Support Software into the US Health System

Echo IQ (ASX:EIQ) deployed EchoSolv AS, its artificial intelligence-based decision support software for the assessment of severe aortic stenosis, into the Mount Sinai Health System in New York, according to a Tuesday filing with the Australian bourse.The company continues to engage with prospective hospitals in the US regarding potential opportunities for the product, the filing said.

$ASX:EIQ